Infliximab (Remicade ®): the magic bullet for Crohn's disease?

Plevy, 1997, A role for TNF-α and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease, J Immunol, 159, 6276, 10.4049/jimmunol.159.12.6276 Reinecker, 1993, Enhanced secretion of tumor necrosis factor-alpha, IL-6 and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease, Clin Exp Immunol, 94, 174, 10.1111/j.1365-2249.1993.tb05997.x Beutler, 1999, The role of tumor necrosis factor in health and disease, J Rheumatol, 26, 16 Murch, 1993, Location of tumor necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease, Gut, 34, 1705, 10.1136/gut.34.12.1705 Knight, 1993, Construction and initial characterization of a mouse-human anti-TNF antibody, Mol Immunol, 30, 1443, 10.1016/0161-5890(93)90106-L Siegel, 1995, The mouse/human chimeric monoclonal antibody cA2 neutralizes in vitro and protects transgenic mice from cachexia and TNF-α lethality in vivo, Cytokine, 7, 15, 10.1006/cyto.1995.1003 Scallon, 1995, Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions, Cytokine, 7, 251, 10.1006/cyto.1995.0029 Targan, 1997, A short term study of chimeric monoclonal antibody (cA2) to tumor necrosis factor α for Crohn's disease, N Engl J Med, 337, 1029, 10.1056/NEJM199710093371502 McCabe, 1996, A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease, Gastroenterology, 110, A962 D'Haens, 1999, Endoscopic and histological healing with infliximab antibodies in Crohn's disease: a European multicenter trial, Gastroenterology, 116, 1029, 10.1016/S0016-5085(99)70005-3 Naert, 1999, Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis, Gastroenterology, 116, 22, 10.1016/S0016-5085(99)70224-6 Rutgeerts, 1999, Efficacy and safety of retreatment with antitumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease, Gastroenterology, 117, 761, 10.1016/S0016-5085(99)70332-X D'Haens, 1999, Duration of response following cessation of infliximab therapy for active and fisulizing Crohn's disease, Gastroenterology, 116, G3029 Maini, 1998, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis Rheum, 41, 1552, 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W Present, 1999, Infliximab for the treatment of fistulas in patients with Crohn's disease, N Engl J Med, 340, 1398, 10.1056/NEJM199905063401804 van der Linde, 2000, Infliximab (Remicade®) for treatment of perineal metastatic Crohn's disease, Gastroenterology, 118, A588, 10.1016/S0016-5085(00)84488-1 Ricart, 2000, Infliximab for Crohn's disease in clinical practice at the Mayo clinic: the first 100 patients, Gastroenterology, 118, A568, 10.1016/S0016-5085(00)84405-4 Toy, 2000, Complete bowel obstruction following initial response to infliximab therapy: a series of a newly described complication, Gastroenterology, 118, A569, 10.1016/S0016-5085(00)84412-1 Braegger, 1999, A multicenter study of Infliximab in the treatment of children with active Crohn's disease, Gut, 45, A262 Hanauer, 1999, Delayed hypersensitivity to infliximab (Remicade) infusion after 2–4 year interval without treatment, Gastroenterology, 116, G3174